Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
Status:
Active, not recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effectiveness of the combination of
nivolumab and abemaciclib for the treatment of hepatocellular carcinoma. Other goals of this
study are to learn about the side effects that this combination of drugs may cause and to
learn more about how these drugs work by studying blood and tissue.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania